Skip Navigation

European Heart Journal 1996 17(Supplement F):16-29; doi:10.1093/eurheartj/17.suppl_F.16
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yusuf, S.
Right arrow Articles by Coutinho, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yusuf, S.
Right arrow Articles by Coutinho, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 1996 The European Society of Cardiology

Treatment for acute myocardial infarction

Overview of randomized clinical trials

S. Yusuf, S. Anand, A. Avezum, Jr, M. Flather and M. Coutinho

Division of Cardiology, McMaster University and Hamilton Civic Hospital Research Centre, Hamilton General Hospital Hamilton, Ontario, Canada

Correspondence. Salim Yusuf, Division of Cardiology, McMaster University, McMaster Clinic, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2

This review summarizes the results of several pharmacological interventions that have been evaluated in the management of acute myocardial infarction. Of these, thrombolytic therapy, aspirin, beta-blockers and angiotensin converting enzyme inhibitors have all been proven to reduce mortality risk and the latter three classes of drugs have also been shown to reduce morbidity. Routine use of heparin or nitrates is not recommended although they may be useful in specific circumstances such as post-infarction angina or large infarcts. Drugs that have as yet not been shown to have a role in the routine management of acute myocardial infarction include Class I antiarrhythmic agents, magnesium and calcium antagonists. Management of patients with acute myocardial infarction can now be appropriately based on the evidence generated from well conducted randomized clinical trials and appropriate therapeutic choices based on such information can be expected to reduce their morbidity and mortality risks.

Key Words: Acute myocardial infarction • drug treatment • randomized clinical trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.